Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Jasper Therapeutics Presented Final Results From Phase 1 Study Of Briquilimab In Patients With AML Or MDS Undergoing Hematopoietic Cell Transplant In Oral Presentation At ASH 2023

Author: Benzinga Newsdesk | December 11, 2023 04:11am

Jasper Therapeutics announced positive final results from the Phase 1 study of briquilimab in combination with fludarabine and low-dose irradiation (Flu/TBI) conditioning in older adults with acute myeloid leukemia (AML) in complete remission (CR) or myelodysplastic syndromes (MDS) undergoing allogeneic hematopoietic cell transplant (HCT)

Posted In: JSPR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist